Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 68Prostatic Neoplasms, Castration-Resistant 6Metastatic Castration-resistant Prostate Cancer 6Neoplasms 4Metastatic Castration Resistant Prostate Cancer 4Urogenital Neoplasms 3Prostate Cancer Metastatic 3Neoplasm Metastasis 3Metastatic Castration-Resistant Prostate Cancer 3Genital Neoplasms, Male 3Breast Neoplasms 3Prostatic Diseases 2Neoplasms by Site 2Genital Diseases, Male 2Carcinoma, Non-Small-Cell Lung 2Parkinson Disease 4, Autosomal Dominant Lewy Body 1Ovarian Neoplasms 1NSCLC Harboring NRG1 Fusion 1Metastatic Castration-sensitive Prostate Cancer 1Metastatic Castration-resistant Prostate Neoplasms 1Metastatic Castration-resistant Prostate Cancer (mCRPC) 1Metastatic Castration-Resistant Prostate Cancer (mCRPC) 1Male Urogenital Diseases 1Hyperaldosteronism 1Colorectal Neoplasms 1Advanced Prostate Cancer 1Advanced Cancer 1Adenocarcinoma 1

Interventions

pembrolizumab 2radium Ra 223 dichloride 1enzalutamide 1efineptakin alfa 1abiraterone 1Radium-223 1Pluvicto 1PSMA-11 1Lutetium-177 1Lutetium 1Injections 1Abiraterone Acetate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Metastatic Castration-resistant Prostate Cancer (mCRPC) × Abiraterone Acetate × Clear all
NCT04862091 2022-03-04

Comparative Study of Abiraterone Acetate Tablets (I) or ZYTIGA® in Patients With Metastatic Castration-resistant Prostate Cancer

Jiangsu HengRui Medicine Co., Ltd.

Phase 2 Completed
69 enrolled
Genitourinary

Metastatic Castration-resistant Prostate Cancer (mCRPC)

Data powered by HemOnc (CC BY 4.0) Colophon âš¡